Long COVID fatigue has left many patients with few real treatment options, but a new randomized trial involving 399 adults suggests fluvoxamine, a widely available, inexpensive antidepressant, might actually help. Participants who took the drug saw significantly less fatigue and reported a better quality of life compared to those on a placebo, marking it as one of the first medications to show a meaningful benefit for this exhausting and often dismissed condition. It’s an encouraging sign for a disease that has left millions searching for answers, and given how cheap and accessible fluvoxamine already is, it could offer a practical option while researchers keep digging into what’s driving long COVID in the first place.
Read more at ScienceDaily